A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Stopped The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.

Conditions

• Breast Cancer

Interventions

• DRUG: Ipatasertib
• DRUG: Placebo
• DRUG: Palbociclib
• DRUG: Fulvestrant

Sponsor

Hoffmann-La Roche